Post‐transplant de novo anti‐HLA donor specific antibodies may contribute to poor graft function after haploidentical haematopoietic stem cell transplantation

Abstract

De novo anti‐HLA donor‐specific antibodies (DSAs) were rarely reported in stem cell transplantation patients. We present a case of 39‐year‐old acute myelogenous leukaemia patient who developed de novo DSAs only 16 days after transplantation with the highest mean fluorescence intensity (MFI) of 7406.23, which were associated with poor graft function (PGF). We used plasma exchange (PE) and intravenous immunoglobulin (IVIg) to reduce DSA level. A series of treatment including mesenchymal stem cells and donor cell transfusion were used to help recover graft function. On day 130, the patient achieved a successful engraftment.